Study identifies 21 drugs that inhibit Sars-CoV-2 replication

Hyperaxion Jul 25, 2020

Research is being carried out on models that simulate human lung tissue. If the results are favorable, scientists intend to start clinical trials with the drugs.

A study by the Sanford Burnham Prebys Medical Discovery Institute, in the United States, identified 21 existing drugs capable of preventing the replication of Sars-CoV-2 in the human body. The discovery was published this week in the journal Nature.

Study identifies 21 drugs that inhibit Sars-CoV-2 replication
(Credit: Unsplash).

The scientists analyzed a list of drugs and confirmed the existence of at least 100 molecules present in these drugs with antiviral activity.

According to the researchers, the dose required to inhibit the new coronavirus is safe and effective for humans in 21 of the drugs analyzed.

In addition, four of the drugs worked in combination with remdesivir, an antiviral that is already used to treat Covid-19.

“Remdesivir has proven successful at shortening the recovery time for patients in the hospital, but the drug doesn’t work for everyone who receives it. That’s not good enough,” said Sumit Chanda, one of the researchers.

One of the researchers during the tests.
One of the researchers during the tests. (Credit: Sanford Burham Prebys Medical Discovery Institute).

Now the team is testing the 21 compounds in small animals and in “mini lungs”, or lung organoids, that mimic human tissue. If the results are favorable, the scientists intend to start clinical trials with the drugs.

“Based on our current analysis, clofazimine, hanfangchin A, apilimod and ONO 5334 represent the best short-term options for effective treatment against Covid-19,” Chanda explained. “We believe it’s important to pursue additional drug candidates so we have multiple therapeutic options if SARS-CoV-2 becomes drug resistant.”

Related topics:

Coronavirus Covid-19

Comments

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments